4
4
1
1
4
4
14
14
5
5
15
15
15
15
12
12
22
22
1
1
2020
2011
Company (117)Investor (19)Hospital (7)University (1)
1 - 10 of 117
Sort by
Patent
Publication NumberUS 20200138791Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-06-17Publication Date2020-05-07
The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
Patent
Publication NumberUS 10501455Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-12-13Publication Date2019-12-10
The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4-h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.
Patent
Publication NumberUS 20190365750Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-05-31Publication Date2019-12-05
Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
Patent
Publication NumberWO 2019232306 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2019-05-31Publication Date2019-12-05
Described are methods of reducing pulmonary exacerbations and methods of treating cystic fibrosis, including methods of reducing pulmonary inflammation, comprising administration of an LTA4h inhibitor.
Patent
Publication NumberBR 112015022864 A8Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2014-03-14Publication Date2019-11-26
The present invention is directed to compounds encompassed by the Formula (I), pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.
Patent
Publication NumberEP 3551611 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-12-11Publication Date2019-10-16
Patent
Publication NumberEP 3551628 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-12-11Publication Date2019-10-16
Patent
Publication NumberEP 3551608 A1Filing StatusPatent ApplicationAvailabilityUnknownFiling Date2017-12-11Publication Date2019-10-16
Patent
Publication NumberUS 10399986Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-09-14Publication Date2019-09-03
The present invention is directed to compounds encompassed by the Formula (I): pharmaceutical compositions thereof, methods for inhibiting LTA-4 hydrolase, and methods for the treatment of a disease and disorder which is ameliorated by the inhibition of LTA4h activity. Non-limiting examples of such diseases and conditions include inflammatory and autoimmune diseases and disorders.
Patent
Publication NumberUS 10385007Filing StatusIssued PatentAvailabilityUnknownFiling Date2017-12-11Publication Date2019-08-20
This present disclosure is directed to compounds of formula (I): where r, q, R1a, R1b, R1c, R1d, R1e, R2, R3, R4a, R5a, R5b, R6a, R6b, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds …
We found 117 documents that match your Search
Patents: 103
Clinical Trials: 10
SEC Filings: 4

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in